Drug Details

General Information of the Drug (ID: DR6690)
Name
Streptomycin
Synonyms
streptomycin; 57-92-1; Streptomycin A; Strepcen; Gerox; Streptomycine; Streptomycin sulphate; Chemform; Streptomycin sulfate; CHEBI:17076; UNII-Y45QSO73OB; Estreptomicina; NSC-14083; Streptomycin A sulfate; Y45QSO73OB; 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside; 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; Agrimycin; Agrept; Neodiestreptopab; Streptomicina; Streptomycinum; Streptomyzin; Hokko-mycin; [2-deoxy-2-(dimethylamino)-alpha-L-glucopyranosyl]-(1->2)-[5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl]-(1->4)-{N',N'''-[(1,3,5/2,4,6)-2,4,5,6-tetrahydroxycyclohexane-1,3-diyl]diguanidine}; 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; SRY; Streptomycin Sesquisulfate Hydrate; Caswell No. 804; Streptomyzin [German]; Streptomicina [Italian]; NCGC00159339-02; Streptomycin [INN:BAN]; Streptomycin, Sulfate Salt; streomycin; Geroxeg; Estreptomicina [INN-Spanish]; CCRIS 5730; HSDB 1768; Streptomycin,(S); 1-[(1S,2R,3R,4S,5R,6R)-2-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)tetrahydropyran-2-yl]oxy-4-formyl-4-hydroxy-5-methyl-tetrahydrofuran-2-yl]oxy-5-guanidino-3,4,6-trihydroxy-cyclohexyl]guanidine; Streptomycin (TN); EINECS 200-355-3; Streptomycin (INN); EPA Pesticide Chemical Code 006306; Liposomal Streptomycin; NSC14083; BRN 0074498; Epitope ID:224553; SCHEMBL3276; 4-18-00-07540 (Beilstein Handbook Reference); D-Streptamine, O-2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl-(1-2)-O-5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl-(1-4)-N,N'-bis(aminoiminomethyl)-; CHEMBL372795; DTXSID4023597; GTPL10923; Streptomycin Sesquisulphate Hydrate; ZINC8214681; BDBM50103513; MFCD00072108; AKOS015969759; AM84920; DB01082; AS-35042; tetrahydro-2H-pyran-2-yloxy)-4-formyl-4; 280-EP2269990A1; 280-EP2270001A1; 280-EP2270006A1; 280-EP2270008A1; 280-EP2270014A1; 280-EP2272832A1; 280-EP2275420A1; 280-EP2275422A1; 280-EP2277861A1; 280-EP2277876A1; 280-EP2277880A1; 280-EP2277898A2; 280-EP2281563A1; 280-EP2281824A1; 280-EP2284154A1; 280-EP2284169A1; 280-EP2284171A1; 280-EP2284172A1; 280-EP2286812A1; 280-EP2287161A1; 280-EP2287162A1; 280-EP2289876A1; 280-EP2289882A1; 280-EP2289886A1; 280-EP2289892A1; 280-EP2289893A1; 280-EP2292088A1; 280-EP2292592A1; 280-EP2292608A1; 280-EP2292610A1; 280-EP2292612A2; 280-EP2292614A1; 280-EP2292617A1; 280-EP2295055A2; 280-EP2295402A2; 280-EP2295411A1; 280-EP2295416A2; 280-EP2295417A1; 280-EP2295434A2; 280-EP2298748A2; 280-EP2301536A1; 280-EP2301538A1; 280-EP2301544A1; 280-EP2301940A1; 280-EP2305033A1; 280-EP2305652A2; 280-EP2305658A1; 280-EP2305662A1; 280-EP2305684A1; 280-EP2305688A1; 280-EP2308562A2; 280-EP2308844A2; 280-EP2308845A2; 280-EP2308846A2; 280-EP2308855A1; 280-EP2308857A1; 280-EP2308872A1; 280-EP2308960A1; 280-EP2311453A1; 280-EP2311455A1; 280-EP2311494A1; 280-EP2311806A2; 280-EP2311836A1; 280-EP2314583A1; 280-EP2316452A1; 280-EP2316459A1; 280-EP2316829A1; 280-EP2316832A1; 280-EP2316833A1; 280-EP2316937A1; 280-EP2371811A2; C00413; D08531; 3-((2S,3S,4S,5R,6S)-4,5-dihydroxy-6; AB00443813_02; 057S921; 2,5,6-trihydroxycyclohexane-1,3-diyl)diguanidine; Q192717; BRD-K07166362-330-02-8; 1,-((1R,2R,3S,4R,5R,6S)-4-((2R,3R,4R,5S)-; 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-glucopyranosyl)-3-formylpentofuranoside; D-Streptamine, O-2-deoxy-2-(methylamino)-.alpha.-L-glucopyranosyl-(1->2)-O-5-deoxy-3-C-formyl-.alpha.-L-lyxofuranosyl-(1->4)-N,N'-bis(aminoiminomethyl)-; D-Streptamine, O-2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl-(1.fwdarw.2)-O-5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl-(1.fwdarw.4)-N,N'-bis(aminoiminomethyl)-; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-{5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyloxy}-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; O-2-Deoxy-2-(methylamino)-.alpha.-L-glucopyranosyl-(1->2)-O-5-deoxy-3-C-formyl-.alpha.-L-lyxofuranosyl-(1->4)-N,N'-bis(aminoiminomethyl)-D-streptamine and Liposome
    Click to Show/Hide
Molecular Type
Small molecule
Disease Bacterial infection [ICD-11: 1A00-1C4Z] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 25-50 mg/L
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1 h
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.78 mL/min/kg
Elimination
Approximately 50% of streptomycin is eliminated in the urine within 24 hours after intravenous or intramuscular administration
Elimination
55% of drug is excreted from urine in the unchanged form
Half-life
The concentration or amount of drug in body reduced by one-half in 2.5 hours
Half-life
The concentration or amount of drug in body reduced by one-half in 4.3 hours
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 34.3888 micromolar/kg/day
Unbound Fraction
The unbound fraction of drug in plasma is 0.65%
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.34 L/kg
Water Solubility
The ability of drug to dissolve in water is measured as 20 mg/mL
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C21H39N7O12
PubChem CID
19649
Canonical SMILES
CC1C(C(C(O1)OC2C(C(C(C(C2O)O)N=C(N)N)O)N=C(N)N)OC3C(C(C(C(O3)CO)O)O)NC)(C=O)O
InChI
1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1
InChIKey
UCSJYZPVAKXKNQ-HZYVHMACSA-N
CAS Number
CAS 57-92-1
ChEBI ID
CHEBI:17076
TTD Drug ID
D0N0EQ
DrugBank ID
DB01082
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Ferutinin      Ferula sinkiangensisK     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Experimental
                    Result(s)		 The combination of 1 with each antitubercular drug led to mutual enhancement of the antimycobacterial activity with isoniazid and ethionamide, while no such effect was observed with rifampin or streptomycin.
          Sanguinarine      Bocconia frutescens     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Escherichia coli Microorganism model Escherichia coli
Klebsiella pneumoniae Microorganism model Klebsiella pneumoniae
                    Experimental
                    Result(s)		 Three-drug combination of sanguinarine + EDTA + streptomycin showed synergistic activity against almost all the strains, as well as a strong reduction in the effective doses of sanguinarine, EDTA and streptomycin.
Target and Pathway
Target(s) Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)  Molecule Info  [4]
References
Reference 1 Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22.
Reference 2 Antimycobacterial activity of ferutinin alone and in combination with antitubercular drugs against a rapidly growing surrogate of Mycobacterium tuberculosis. Nat Prod Res. 2011 Jul;25(12):1142-9.
Reference 3 Synergistic antibacterial activity of the combination of the alkaloid sanguinarine with EDTA and the antibiotic streptomycin against multidrug resistant bacteria. J Pharm Pharmacol. 2015 Feb;67(2):264-73.
Reference 4 Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 2000 Sep 21;407(6802):340-8.
 Download Picture         KEGG Link